Erin Wysong Hofstatter, MD, associate professor at Yale Cancer Center and co-director of the Cancer Genetics and Prevention Program, discusses the actionable mutations that impact treatment and surgical decisions in breast cancer.
Erin Wysong Hofstatter, MD
Advertisement
Articles by Erin Wysong Hofstatter, MD
Advertisement
Latest Updated Articles
Actionable Mutations Impacting Breast Cancer TreatmentPublished: October 17th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
